In their report that has received advance online publication in Nature Nanotechnology, a research team
based at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) describes how a nanomedicine that combines
photodynamic therapy — the use of light to trigger a chemical reaction — with a molecular
therapy drug targeted against common treatment resistance pathways reduced a thousand-fold the dosage of the molecular
therapy drug required to suppress tumor progression and metastatic outgrowth in an animal model.